HARP News and Press, Harpoon Therapeutics Inc. From 01/10/24

NEW YORK, NY / ACCESSWIRE / January 10, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Harpoon Therapeutics, Inc. (NASDAQ...

2024-01-09 09:58:01 ET More on Harpoon Therapeutics Harpoon: HPN328 Data In 1st Half Of 2024 Makes This A Must Watch Biggest stock movers today: Boeing, American Eagle Outfitters, Harpoon Therapeutics, Ambrx, and more Merck to buy Harpoon in $680M all-cash deal (upda...

2024-01-08 12:31:47 ET More on Merck Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls Merck: Smart Value For Potentially Strong Total Returns Merck to buy Harpoon in $680M all-cash deal (update) For further details see: Merck on tra...

2024-01-08 12:31:25 ET Gainers: Harpoon Therapeutics ( HARP ) +112% . Ambrx Biopharma ( AMAM ) +101% . Nkarta ( NKTX ) +47% . Mountain Crest Acquisition Corp IV ( MCAF ) +45% . Spectaire Holdings ( SPEC ) +43% . Neximmune ( ...

MONSEY, N.Y., Jan. 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $23.00 per share in cash pursuant to which Harpoon Therapeutics, Inc. (Nasdaq: HARP) (“Harpoon”) has agreed to be sold to Merck & Co., Inc. (...

2024-01-08 08:53:00 ET U.S. stock index futures on Monday pointed to a mixed open for Wall Street, as the first full trading week of the new year begins. The benchmark S&P 500 ( SP500 ) last week was unable to extend its blistering year-end 2023 rally. Here are some stocks to wa...

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics...

2024-01-08 06:51:56 ET Summary Boeing and Spirit AeroSystems stocks drop after mid-air blowout incident involving a Boeing plane model. Merck is in talks to acquire Harpoon Therapeutics for around $700 million. Audacy files for bankruptcy as ad sales decline, plans to restruct...

2024-01-08 05:33:37 ET Related stock stories: Boeing: A New Explosive MAX And Stock Crisis? Boeing: The Real Cash Flow Growth Surprise Boeing: $10 Billion FCF Target Appears Realistic By FY25/26, Buy Shares of Boeing and Spirit AeroSystems plunge after mid-ai...

2024-01-08 02:39:13 ET Merck ( NYSE: MRK ) is reportedly in advanced talks to buy immuno-oncology company Harpoon Therapeutics ( NASDAQ: HARP ) for around $700M. Citing people familiar with the matter, Bloomberg News reported on Sunday that Merck ( MRK ) is discu...